Sales Performance - Brinker's same store sales increased by 13% in Q1 F25 and 18.8% in Q1 F26[6] - Chili's same store sales increased by 14.1% in Q1 F25 and 21.4% in Q1 F26[6] - Maggiano's same store sales increased by 4.2% in Q1 F25 but decreased by 6.4% in Q1 F26[6] - Domestic franchise same store sales increased by 12.3% in Q1 F25 and 23.1% in Q1 F26[6] - International franchise same store sales increased by 3.7% in Q1 F25 and 16.5% in Q1 F26[6] - Chili's company sales were $1.019 billion in Q1 F25 and $1.197 billion in Q1 F26[8] - Maggiano's company sales were $108 million in Q1 F25 and $149 million in Q1 F26[8] - Total company sales were $1.127 billion in Q1 F25 and $1.346 billion in Q1 F26[10] - Total revenues were $1.139 billion in Q1 F25 and $1.358 billion in Q1 F26[11] Cost Management - Food cost increased by 120 bps due to unfavorable menu mix, offset by commodity inflation (40 bps) and menu price (-100 bps)[13] - Labor cost decreased by 150 bps due to sales leverage, offset by hourly labor (60 bps), manager salaries (10 bps), and other (340 bps)[15] - Restaurant expense decreased significantly by 310 bps due to sales leverage[16, 17]

Summary of MicroPort (0853) Conference Call Company Overview - **Company**: MicroPort (0853 HK) - **Industry**: Healthcare, specifically medical devices Key Points Financial Performance - **1H2025 Results**: - Sales decline of less than 4% (excluding forex effects) - Adjusted net loss limited to US$110 million [1][5] - **Challenges**: - Domestic competition intensifying - Policy-induced price adjustments - International trade conflicts affecting sales growth across all segments, except for the surgical robot business [1][5] Future Outlook - **2H2025 Expectations**: - Anticipated recovery in sales momentum, particularly in the endovascular business during 2Q2025 - Significant growth potential in the surgical robot business as procurement funding in China normalizes [1][5] - **Management Comments**: - Awaiting insights on each business segment, especially orthopedics and CRM, during the interim earnings call [1][5] Investment Thesis - **Profitability Outlook**: - Expected decrease in net loss and potential for profitability by 2026, as per performance covenants from recent financing [5] - **Cost Optimization**: - Targeted cost optimization and inter-segment sales leverage expected to reduce opex/sales ratio from 96% in 2023 to below 50% by 2026 [5] - **Sales Growth**: - Estimated sales growth of approximately 20% per annum [5] Valuation - **Price Target**: - Dec-25 price target set at HK$8.60 based on DCF valuation [6] - **WACC Assumptions**: - Risk-free rate: 3.8% - Market risk premium: 6.4% - Beta: 1.5 - WACC: 12.7% [8] Risks - **Downside Risks**: - Worse-than-expected earnings - Higher-than-expected financial obligations, including CRM share repurchase - Dilution risk from further equity financing - Geopolitical risks [9] Additional Insights - **Convertible Loans**: - Adjusted net loss must not exceed US$110 million in 1H25 and US$55 million in 2025 as per performance covenant [1][5] - **Market Position**: - MicroPort manufactures high-value medical devices used across various disease areas, indicating a broad market presence [5] This summary encapsulates the critical financial and operational insights from the conference call regarding MicroPort, highlighting both current challenges and future opportunities within the healthcare sector.